Document is current

Any future updates will be listed below

Response to Letter to the Editor Regarding: Indirect Treatment Comparison of Inotuzumab Ozogamicin versus Blinatumomab for Relapsed or Refractory Acute Lymphoblastic Leukemia

Crossref DOI link: https://doi.org/10.1007/s12325-019-01169-0

Published Online: 2019-12-14

Published Print: 2020-02

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark